Rae S M Yeung

List of Publications by Year
in descending order

128 papers	5,565 citations	70961 41 h-index	91712 69 g-index
137 all docs	137 docs citations	137 times ranked	5991 citing authors

#	Article	IF	Citations
1	Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis. Rheumatology, 2023, 62, SI170-SI180.	0.9	4
2	Costs of <scp>Hospitalâ€Associated</scp> Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System. Arthritis Care and Research, 2022, 74, 1585-1592.	1.5	3
3	Phase <scp>IIa</scp> Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis. Arthritis and Rheumatology, 2022, 74, 124-133.	2.9	12
4	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARSâ€“CoVâ€2 and Hyperinflammation in Pediatric COVIDâ€19: Version 3. Arthritis and Rheumatology, 2022, 74, .	2.9	146
5	The Long-term Cardiac and Noncardiac Prognosis of Kawasaki Disease: A Systematic Review. Pediatrics, 2022, 149, .	1.0	2
6	Wide variation in glucocorticoid dosing in paediatric ANCA-associated vasculitis with renal disease: a paediatric vasculitis initiative study. Clinical and Experimental Rheumatology, 2022, , .	0.4	1
7	Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study. Patient, 2022, 15, 599-609.	1.1	3
8	Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis. Rheumatology and Therapy, 2022, 9, 721-734.	1.1	2
9	A Comparison of International League of Associations for Rheumatology and Pediatric Rheumatology International Trials Organization Classification Systems for Juvenile Idiopathic Arthritis Among Children in a Canadian Arthritis Cohort. Arthritis and Rheumatology, 2022, 74, 1409-1419.	2.9	7
10	Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study. Pediatric Rheumatology, 2022, 20, 25.	0.9	8
11	An Update on Childhood-Onset Takayasu Arteritis. Frontiers in Pediatrics, 2022, 10, 872313.	0.9	6
12	Paediatric-to-adult transition experience in vasculitis: report of a model of care and outcomes.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
13	Gene Expression Profiles of Treatment Response and <scp>Nonâ€Response</scp> in Children With Juvenile Dermatomyositis. ACR Open Rheumatology, 2022, 4, 671-681.	0.9	4
14	Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 975-984.	0.7	8
15	Soluble Low-density Lipoprotein Receptor-related Protein 1 in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2021, 48, 760-766.	1.0	0
16	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARSâ€“CoVâ€2 and Hyperinflammation in Pediatric COVIDâ€19: Version 2. Arthritis and Rheumatology, 2021, 73, e13-e29.	2.9	314
17	MIS-C: early lessons from immune profiling. Nature Reviews Rheumatology, 2021, 17, 75-76.	3.5	51
18	CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update. Journal of Rheumatology, 2021, 48, 555-566.	1.0	27

#	Article	IF	Citations
19	Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nature Reviews Rheumatology, 2021, 17, 257-269.	3.5	52
20	Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis â€“ Two Ends of the Same Spectrum. Frontiers in Pediatrics, 2021, 9, 665815.	0.9	10
21	Reply. Arthritis and Rheumatology, 2021, 73, 1342-1343.	2.9	0
22	Prognostic Factors and Long-Term Outcome with ANCA-Associated Kidney Vasculitis in Childhood. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1043-1051.	2.2	19
23	Clinical and psychosocial stress factors are associated with decline in physical activity over time in children with juvenile idiopathic arthritis. Pediatric Rheumatology, 2021, 19, 97.	0.9	8
24	Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study. Rheumatology and Therapy, 2021, 8, 1303-1322.	1.1	6
25	Biologic medicine inclusion in 138 national essential medicines lists. Pediatric Rheumatology, 2021, 19, 140.	0.9	0
26	The promise of machine learning to inform the management of juvenile idiopathic arthritis. Expert Review of Clinical Immunology, 2021, 17, 1-3.	1.3	3
27	Genomic Health Literacy Interventions in Pediatrics: Scoping Review. Journal of Medical Internet Research, 2021, 23, e26684.	2.1	4
28	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARSâ€“CoVâ€2 and Hyperinflammation in Pediatric COVIDâ€19: Version 1. Arthritis and Rheumatology, 2020, 72, 1791-1805.	2.9	323
29	Pediatric inflammatory multisystem syndrome temporally associated with COVID-19: a spectrum of diseases with many names. Cmaj, 2020, 192, E1093-E1096.	0.9	24
30	Treatment-associated hemolysis in Kawasaki disease: association with blood-group antibody titers in IVIG products. Blood Advances, 2020, 4, 3416-3426.	2.5	16
31	A Canadian evaluation framework for quality improvement in childhood arthritis: key performance indicators of the process of care. Arthritis Research and Therapy, 2020, 22, 53.	1.6	8
32	A Clinically and Biologically Based Subclassification of the Idiopathic Inflammatory Myopathies Using Machine Learning. ACR Open Rheumatology, 2020, 2, 158-166.	0.9	12
33	Clinical and associated inflammatory biomarker features predictive of short-term outcomes in non-systemic juvenile idiopathic arthritis. Rheumatology, 2020, 59, 2402-2411.	0.9	11
34	Stability of 40 cytokines/chemokines in chronically ill patients under different storage conditions. Cytokine, 2020, 130, 155057.	1.4	7
35	Associations of clinical and inflammatory biomarker clusters with juvenile idiopathic arthritis categories. Rheumatology, 2020, 59, 1066-1075.	0.9	9
36	Is multisystem inflammatory syndrome in children on the Kawasaki syndrome spectrum?. Journal of Clinical Investigation, 2020, 130, 5681-5684.	3.9	20

#	Article	IF	Citations
37	Increased Arterial Stiffness Adversely Affects Left Ventricular Mechanics in Patients With Pediatric Takayasu Arteritis From a Toronto Cohort. Journal of Clinical Rheumatology, 2019, 25, 171-175.	0.5	8
38	Presentation and Disease Course of Childhoodâ€Onset Versus Adultâ€Onset Takayasu Arteritis. Arthritis and Rheumatology, 2019, 71, 315-323.	2.9	38
39	Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist. Pediatric Rheumatology, 2019, 17, 31.	0.9	17
40	320.â€ƒPEDIATRIC OPEN-LABEL CLINICAL STUDY OF RITUXIMAB FOR THE TREATMENT OF GRANULOMATOSIS WITH POLYANGIITIS AND MICROSCOPIC POLYANGIITIS. Rheumatology, 2019, 58, .	0.9	1
41	Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review. Pediatric Rheumatology, 2019, 17, 20.	0.9	10
42	Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis. Arthritis and Rheumatology, 2019, 71, 1747-1755.	2.9	41
43	Extensive Ethnic Variation and Linkage Disequilibrium at the FCGR2/3 Locus: Different Genetic Associations Revealed in Kawasaki Disease. Frontiers in Immunology, 2019, 10, 185.	2.2	43
44	A combined immunodeficiency with severe infections, inflammation, and allergy caused by ARPC1B deficiency. Journal of Allergy and Clinical Immunology, 2019, 143, 2296-2299.	1.5	87
45	Treatment of rituximab-associated chronic CNS enterovirus using IVIg and fluoxetine. Neurology, 2019, 92, 916-918.	1.5	8
46	Patterns of joint involvement in juvenile idiopathic arthritis and prediction of disease course: A prospective study with multilayer non-negative matrix factorization. PLoS Medicine, 2019, 16, e1002750.	3.9	36
47	THU0525â€…DEVELOPMENT OF A PREDICTIVE TOOL FOR RESPONSE TO ANTI-TNF-ALPHA THERAPY IN JIA USING GENE EXPRESSION PROFILES IN PERIPHERAL DERIVED MONONUCLEAR CELLS. , 2019, , .		0
48	Reply. Arthritis and Rheumatology, 2019, 71, 836-838.	2.9	0
49	Prospective Determination of the Incidence and Risk Factors of Newâ€Onset Uveitis in Juvenile Idiopathic Arthritis: The Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort. Arthritis Care and Research, 2019, 71, 1436-1443.	1.5	26
50	Kawasaki Disease-Associated Cytokine Storm Syndrome. , 2019, , 393-406.		6
51	IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukinâ€1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2018, 70, 1319-1330.	2.9	40
52	Brief Report: The Genetic Profile of Rheumatoid Factorâ€“Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 957-962.	2.9	53
53	Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study. Pediatric Rheumatology, 2018, 16, 17.	0.9	8
54	The immune-stimulation capacity of liposome-treated red blood cells. Journal of Liposome Research, 2018, 28, 173-181.	1.5	5

#	Article	IF	Citations
55	Healthâ€Related Quality of Life in an Inception Cohort of Children With Juvenile Idiopathic Arthritis: A Longitudinal Analysis. Arthritis Care and Research, 2018, 70, 134-144.	1.5	50
56	Trajectories of pain severity in juvenile idiopathic arthritis: results from the Research in Arthritis in Canadian Children Emphasizing Outcomes cohort. Pain, 2018, 159, 57-66.	2.0	29
57	Evaluation of the functional properties of cryopreserved buffy coatâ€“derived monocytes for monocyte monolayer assay. Transfusion, 2018, 58, 2027-2035.	0.8	4
58	Environmental epidemiology of Kawasaki disease: Linking disease etiology, pathogenesis and global distribution. PLoS ONE, 2018, 13, e0191087.	1.1	53
59	Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment. International Journal of Cardiology, 2017, 236, 157-161.	0.8	38
60	Loss of the Arp2/3 complex component ARPC1B causes platelet abnormalities and predisposes to inflammatory disease. Nature Communications, 2017, 8, 14816.	5.8	176
61	Early Outcomes in Children With Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 1470-1479.	2.9	56
62	Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Annals of the Rheumatic Diseases, 2017, 76, 906-913.	0.5	123
63	Outcome of kidney transplantation in pediatric patients with ANCA-associated glomerulonephritis: a single-center experience. Pediatric Nephrology, 2017, 32, 2343-2350.	0.9	12
64	Revisiting the role of steroids and aspirin in the management of acute Kawasaki disease. Current Opinion in Rheumatology, 2017, 29, 547-552.	2.0	10
65	A Toddler Presenting with Pulmonary Renal Syndrome. Case Reports in Nephrology and Dialysis, 2017, 7, 73-80.	0.3	4
66	Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Pediatric Rheumatology, 2017, 15, 68.	0.9	39
67	Childhood Takayasu arteritis: disease course and response to therapy. Arthritis Research and Therapy, 2017, 19, 255.	1.6	54
68	Update on Pathogenesis: Lessons Learned from Animal Models of Disease. , 2017, , 45-51.		1
69	Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study. Arthritis and Rheumatology, 2016, 68, 2514-2526.	2.9	103
70	Malignancy incidence in 5294 patients with juvenile arthritis. RMD Open, 2016, 2, e000212.	1.8	9
71	Arterial dissection in childhood Takayasu Arteritis: not as rare as thought. Pediatric Rheumatology, 2016, 14, 56.	0.9	13
72	Variability in Response to Intravenous Immunoglobulin in the Treatment of Kawasaki Disease. Journal of Pediatrics, 2016, 179, 124-130.e1.	0.9	16

#	Article	IF	Citations
73	Inositol-Triphosphate 3-Kinase C Mediates Inflammasome Activation and Treatment Response in Kawasaki Disease. Journal of Immunology, 2016, 197, 3481-3489.	0.4	99
74	Enhancing translational research in paediatric rheumatology through standardization. Nature Reviews Rheumatology, 2016, 12, 684-690.	3.5	13
75	Genetic Variation in the SLC8A1 Calcium Signaling Pathway Is Associated With Susceptibility to Kawasaki Disease and Coronary Artery Abnormalities. Circulation: Cardiovascular Genetics, 2016, 9, 559-568.	5.1	45
76	TNF and IL-1 Targeted Treatment in Kawasaki Disease. Current Treatment Options in Rheumatology, 2016, 2, 283-295.	0.6	8
77	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nature Communications, 2016, 7, 12460.	5.8	73
78	The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2016, 75, 1092-1098.	0.5	72
79	Gene Expression Deconvolution for Uncovering Molecular Signatures in Response to Therapy in Juvenile Idiopathic Arthritis. PLoS ONE, 2016, 11, e0156055.	1.1	8
80	HLA-DRB1*11and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	3.3	139
81	The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2015, 74, 1854-1860.	0.5	192
82	Imaging of systemic vasculitis in childhood. Pediatric Radiology, 2015, 45, 1110-1125.	1.1	24
83	A159: The Autoimmune Genetic Architecture of Childhood Onset Rheumatoid Arthritis. Arthritis and Rheumatology, 2014, 66, S205-S206.	2.9	0
84	Description of Active Joint Count Trajectories in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2014, 41, 2466-2473.	1.0	16
85	The Biologic Basis of Clinical Heterogeneity in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, 3463-3475.	2.9	69
86	Atorvastatin Safety in Kawasaki Disease Patients With Coronary Artery Aneurysms. Pediatric Cardiology, 2014, 35, 89-92.	0.6	26
87	Factors Associated With Low Moderate-to-Vigorous Physical Activity Levels in Pediatric Patients With Kawasaki Disease. Clinical Pediatrics, 2012, 51, 828-834.	0.4	12
88	Corticosteroid administration for patients with coronary artery aneurysms after Kawasaki disease may be associated with impaired regression. International Journal of Cardiology, 2012, 154, 9-13.	0.8	33
89	Epidemiology and Management of Kawasaki Disease. Drugs, 2012, 72, 1029-1038.	4.9	56
90	Complete and incomplete Kawasaki disease: two sides of the same coin. European Journal of Pediatrics, 2012, 171, 657-662.	1.3	72

#	Article	IF	Citations
91	Rate, associated factors and outcomes of recurrence of Kawasaki disease in Ontario, Canada. Pediatrics International, 2012, 54, 383-387.	0.2	22
92	Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nature Genetics, 2011, 43, 1241-1246.	9.4	297
93	Inhibition of Transforming Growth Factor Î² Worsens Elastin Degradation in a Murine Model of Kawasaki Disease. American Journal of Pathology, 2011, 178, 1210-1220.	1.9	19
94	The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease. Clinical and Experimental Immunology, 2011, 164, 193-201.	1.1	36
95	Intravenous immunoglobulin preparation type: Association with outcomes for patients with acute Kawasaki disease. Pediatric Allergy and Immunology, 2010, 21, 515-521.	1.1	26
96	Macrophage Activation Syndrome in the Acute Phase of Kawasaki Disease. Journal of Pediatric Hematology/Oncology, 2010, 32, 527-531.	0.3	77
97	Kawasaki disease: update on pathogenesis. Current Opinion in Rheumatology, 2010, 22, 551-560.	2.0	90
98	Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care and Research, 2010, 62, 527-536.	1.5	86
99	Repeated systematic surveillance of Kawasaki disease in Ontario from 1995 to 2006. Pediatrics International, 2010, 52, 699-706.	0.2	64
100	Factors Associated with a Longer Time to Access Pediatric Rheumatologists in Canadian Children with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2010, 37, 2415-2421.	1.0	16
101	Parental Anxiety Associated With Kawasaki Disease in Previously Healthy Children. Journal of Pediatric Health Care, 2010, 24, 250-257.	0.6	18
102	Kawasaki Disease at the Extremes of the Age Spectrum. Pediatrics, 2009, 124, e410-e415.	1.0	87
103	Comparison of Factors Associated With Coronary Artery Dilation Only Versus Coronary Artery Aneurysms in Patients With Kawasaki Disease. American Journal of Cardiology, 2009, 104, 1743-1747.	0.7	58
104	Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: Results of a Canadian multicenter, prospective inception cohort study. Arthritis and Rheumatism, 2009, 61, 1077-1086.	6.7	68
105	Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Arthritis and Rheumatism, 2009, 60, 2131-2141.	6.7	48
106	Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. Clinical and Experimental Immunology, 2009, 157, 300-309.	1.1	49
107	Coronary artery dilation after Kawasaki disease for children within the normal range. International Journal of Cardiology, 2009, 136, 27-32.	0.8	35
108	Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. Arthritis and Rheumatism, 2008, 58, 854-863.	6.7	74

#	Article	IF	Citations
109	Asking the experts: Exploring the selfâ€management needs of adolescents with arthritis. Arthritis and Rheumatism, 2008, 59, 65-72.	6.7	122
110	Assessment of sample collection and storage methods for multicenter immunologic research in children. Journal of Immunological Methods, 2008, 339, 82-89.	0.6	47
111	Echocardiographic and electrocardiographic trends in children with acute Kawasaki disease. Canadian Journal of Cardiology, 2008, 24, 776-780.	0.8	34
112	Elastolytic Matrix Metalloproteinases and Coronary Outcome in Children with Kawasaki Disease. Pediatric Research, 2007, 61, 710-715.	1.1	19
113	Phenotype and coronary outcome in Kawasaki's disease. Lancet, The, 2007, 369, 85-87.	6.3	11
114	Lessons learned from an animal model of Kawasaki disease. Clinical and Experimental Rheumatology, 2007, 25, S69-71.	0.4	9
115	Arthritis presenting during the acute phase of Kawasaki disease. Journal of Pediatrics, 2006, 148, 800-805.	0.9	93
116	TNF-Î± Is Necessary for Induction of Coronary Artery Inflammation and Aneurysm Formation in an Animal Model of Kawasaki Disease. Journal of Immunology, 2006, 176, 6294-6301.	0.4	156
117	Corticosteroid treatment of refractory Kawasaki disease. Journal of Rheumatology, 2006, 33, 803-9.	1.0	25
118	Pathogenesis and treatment of Kawasaki??s disease. Current Opinion in Rheumatology, 2005, 17, 617-623.	2.0	38
119	Infections and Kawasaki Disease: Implications for Coronary Artery Outcome. Pediatrics, 2005, 116, e760-e766.	1.0	127
120	Longterm outcomes in patients with giant aneurysms secondary to Kawasaki disease. Journal of Rheumatology, 2005, 32, 928-34.	1.0	35
121	Presence of IFN-Î³ Does Not Indicate Its Necessity for Induction of Coronary Arteritis in an Animal Model of Kawasaki Disease. Journal of Immunology, 2004, 173, 3492-3503.	0.4	30
122	The etiology of Kawasaki disease: a superantigen-mediated process. Progress in Pediatric Cardiology, 2004, 19, 115-122.	0.2	20
123	The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss. Journal of Rheumatology, 2004, 31, 844-6.	1.0	12
124	Kawasaki disease and scald injuries: a possible association. Canadian Journal of Cardiology, 2004, 20, 1147-9.	0.8	7
125	Superantigenic activity is responsible for induction of coronary arteritis in mice: an animal model of Kawasaki disease. International Immunology, 2003, 15, 79-89.	1.8	75
126	Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. Journal of Pediatrics, 2002, 140, 450-455.	0.9	119

#	Article	IF	Citations
127	Generation of Humanized Mice Susceptible to Peptide-Induced Inflammatory Heart Disease. Circulation, 1999, 99, 1885-1891.	1.6	43
128	Human CD4 and human major histocompatibility complex class II (DQ6) transgenic mice: supersensitivity to superantigen-induced septic shock. European Journal of Immunology, 1996, 26, 1074-1082.	1.6	58